• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • UK / Ireland

Sofinnova leads £15m round for Green Biologics

  • Ellie Pullen
  • 02 December 2013
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Sofinnova Partners has led a £15.4m series-B funding round for Green Biologics, a UK-based chemicals producer, alongside Hong Kong-based Swire Pacific and several existing investors.

Capricorn Venture Partners, Oxford Capital Partners (OCP), Morningside Ventures and Convergince Holdings reinvested in Green Biologics as part of the round.

The fresh funding will be used by the company to finance the eventual launch of its first commercial production facility in the US, due to take place in 2016.

Green Biologics

  • DEAL:

    Expansion

  • VALUE:

    £15.4m

  • LOCATION:

    Abingdon

  • SECTOR:

    Speciality chemicals

  • FOUNDED:

    2003

  • STAFF:

    40

Previous funding
In November 2007, OCP led a £1.6m series-A round for the company, with participation from angel investors and Carbon Trust Investments. Prior to this round, Green Biologics had completed a couple of seed funding rounds with a combined value of around £370,000, according to its website.

In February 2009, the company received a further £1m from OCP, Carbon Trust and Morningside. This was followed in May 2010 with OCP, Capricorn, Carbon Trust and Morningside committing £4.9m to Green Biologics.

In May last year, Capricorn, OCP and Morningside injected a further £3.2m into the company. The three firms then provided an additional £2m to the company in July this year.

Company
Founded in 2003, Green Biologics is headquartered in Abingdon with an additional office in Ashland, Virginia, and a laboratory located in Columbus, Ohio. The company employs 40 staff.

Green Biologics has developed fermentation technology for the production of renewable C4 chemicals, with a core focus on the manufacturing of n-butanol. The chemical n-butanol is used in food and drink, household cleaning products, paints, adhesives, inks, plastics and pharmaceuticals. The global n-butanol market exceeds $6bn, according to Green Biologics.

The company produces renewable n-butanol from feedstocks such as grasses, corn, sugar beets and sugar cane. By using feedstocks, the company has access to lower-cost sugars.

People
Sean Sutcliffe is the CEO of Green Biologics. The company's board of directors includes Capricorn senior investment manager Claude Stoufs, OCP operating partner David Brister and Morningside's Reenie McCarthy. Denis Lucquin is a managing partner at Sofinnova.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • UK / Ireland
  • Industrials
  • Expansion
  • United Kingdom
  • Sofinnova Partners

More on UK / Ireland

Fund closes in US dollars
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • Funds
  • 05 September 2023
Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
Public sector software
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • Exits
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013